Dan Keret
Scientific Advisory Panel Member
Radiology
BioMarCare Technologies
Israel
Biography
The company's Multi-Biomarker Panel approach, combined with its technological and clinical expertise, promises to generate molecular blood tests as well as tissue-based diagnostic (IHC) tests with high specificity and sensitivity. Cancer has attracted a great deal of interest as the area of choice for the development of biomarker-based diagnostics. Until superior therapeutic treatments are developed to prevent, treat and cure cancer, the best means of reducing mortality and morbidity in a disease this complex is early detection and diagnosis
Research Interest
The company's Multi-Biomarker Panel approach, combined with its technological and clinical expertise, promises to generate molecular blood tests as well as tissue-based diagnostic (IHC) tests with high specificity and sensitivity. Cancer has attracted a great deal of interest as the area of choice for the development of biomarker-based diagnostics. Until superior therapeutic treatments are developed to prevent, treat and cure cancer, the best means of reducing mortality and morbidity in a disease this complex is early detection and diagnosis
